Clinical trials: Nonalcoholic Fatty Liver
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males
1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2.
- Trial name
- NCT06308861
- Testing
- Single administration Amg dose Group, Single administration Bmg dose Group, Single administration Cmg dose Group
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Fatty Liver Disease, Chronic Glomerular Disease
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
The association of metabolic associated fatty liver disease in patients with chronic glomerular disease
- Trial name
- NCT06691529
- Volunteers
- 500 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Endoscopic weight loss procedures, also termed endoscopic sleeve gastroplasty (ESG), has been proposed as a non-surgical procedure for managing obesity and offers a standard weight loss approach.
- Trial name
- NCT05507151
- Testing
- Endoscopic Sleeve Gastroplasty
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Virginia University
Nonalcoholic Fatty Liver
Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
This study is a prospective, observational, single-center, short-term cross-sectional study to assess the repeatability and reproducibility of a set of specified MRI quantitative biomarkers.
- Trial name
- NCT05081427
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Non Alcoholic Fatty Liver Disease
Mastiha Treatment for Obese With NAFLD Diagnosis
NAFLD/NASH is one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients.
- Trial name
- MAST4HEALTH (NCT03135873)
- Testing
- Mastiha
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Harokopio University
NAFLD, Obesity
Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)
Epidemiological data and studies in animal models suggest, that polyunsatured fatty acids (PUFA) rather than mono-unsatured fatty acids (MUFA) are associated with lower hepatic lipid content (HCL) and may facilitate a decrease of…
- Conditions
- NAFLD, Obesity, Prediabetes, Dyslipoproteinemia
- Trial name
- UFOP-2 (NCT02458586)
- Testing
- Dietary intervention / counseling
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- German Institute of Human Nutrition
Non-alcoholic Fatty-liver Disease
Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis
Primary Objectives: 1. To determine whether a 4 week reduction in dietary fructose intake improves hepatic steatosis in overweight children who have a baseline high fructose consumption and hepatic steatosis. 2.
- Trial name
- Sweet Bev (NCT01188083)
- Testing
- Fructose Drink, Glucose Drink
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Emory University
Nonalcoholic Steatohepatitis (NASH)
The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects
This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of HEC96719, in healthy subjects.This study is the healthy adult subjects single ascending-dose research
- Trial name
- NCT04194242
- Testing
- HEC96719 tablets
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States.
- Trial name
- NCT04031729
- Testing
- Aspirin 81 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Obesity, Morbid, NASH
The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis
Background: Ketosis after bariatric surgery is a metabolic process that occurs when the body breaks down fat for energy because of not getting enough carbohydrates.
- Conditions
- Obesity, Morbid, NASH, Ketosis, Keto Acidosis
- Trial name
- NCT06338969
- Testing
- Carbohydrate Restriction after a Gastric Bypass
- Where
- Kazakhstan
- Volunteers
- 150 people
- Sponsor
- The Society of Bariatric and Metabolic Surgeons of Kazakhstan
Visceral Obesity, Non-alcoholic Fatty Liver
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
This study aims to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat, as well as their…
- Conditions
- Visceral Obesity, Non-alcoholic Fatty Liver, Postmenopausal
- Trial name
- FATHIS+ (NCT06377631)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- 2 sites in Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Non-alcoholic Steatohepatitis
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
The aim of this study is to evaluate the efficacy of metadoxine as a therapy for patients with biopsy-proven non-alcoholic steatohepatitis.
- Trial name
- NCT02541045
- Testing
- metadoxine
- Where
- Mexico
- Sponsor
- Hospital General de Mexico
Type 2 Diabetes, NAFLD
Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients
Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and…
- Trial name
- NIMROD (NCT05654805)
- Testing
- Drinking powder supplement
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- Charite University, Berlin, Germany
Non-alcoholic Fatty Liver Disease, Vitamin D Deficiency
Vitamin D in Fatty Liver Disease
This study evaluates the influence of vitamin D in reducing laboratory, elastographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive vitamin D (Plivit D3) while the other half will receive placebo
- Trial name
- NCT04038853
- Testing
- 1,25-Dihydroxyvitamin D
- Volunteers
- 360 people
- Sponsor
- University Hospital Rijeka
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease
Diabetes, Exercise and Liver Fat (DELIVER)
This randomised controlled trial will determine if exercise (150 - 200 min per week, 6 weeks) can beneficially modify liver fat quality in non alcohol fatty liver disease patients with type 2 diabetes mellitus (n = 26, 13 per…
- Conditions
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity, Insulin Resistance
- Trial name
- (DELIVER) (NCT04004273)
- Testing
- Exercise
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- James King
Non-Alcoholic Fatty Liver Disease
Smartphone App for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a disease spectrum that encompasses excessive liver deposition of fat (NAFL), non-alcoholic steatohepatitis (NASH), and NASH cirrhosis.
- Trial name
- AppLiver (NCT05180760)
- Testing
- Smartphone app use, Standard of care
- Where
- China
- Volunteers
- 260 people
- Sponsor
- The University of Hong Kong
NASH, NAFLD
Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for approximately 36% of liver-related deaths and over one…
- Trial name
- MODELS (NCT06888310)
- Testing
- extra blood sampling
- Where
- Italy
- Volunteers
- 408 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
The Olmsted NAFLD Epidemiology Study (TONES)
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate…
- Trial name
- NCT04365855
- Testing
- Magnetic Resonance Elastography, Blood draw, Liver biopsy
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Mayo Clinic
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University